Company Description

Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on reversing biological aging and degenerative diseases.

It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Progeria, Wilson’s disease, and age-related macular degeneration (amd), as well as type 2 diabetes, cancer, and Alzheimer’s disease.

The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022.

Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.

Telomir Pharmaceuticals, Inc.

Country	United States
Founded	2021
IPO Date	Feb 9, 2024
Industry	Biotechnology
Sector	Healthcare
Employees	9
CEO	Erez Aminov

Contact Details

Address: 100 SE 2nd Street, Suite 2000 #1009 Miami, Florida 33131 United States
Phone	786 396 6723
Website	telomirpharma.com

Stock Details

Ticker Symbol	TELO
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$7.00
CIK Code	0001971532
CUSIP Number	87975F104
ISIN Number	US87975F1049
Employer ID	87-2606031
SIC Code	2834

Key Executives

Name	Position
Erez Aminov	Chairman of the Board and Chief Executive Officer

Latest SEC Filings

Date	Type	Title
Jun 18, 2025	8-K	Current Report
Jun 11, 2025	8-K	Current Report
Jun 5, 2025	8-K	Current Report
Jun 2, 2025	8-K	Current Report
May 29, 2025	8-K	Current Report
May 21, 2025	8-K	Current Report
May 21, 2025	8-K	Current Report
May 15, 2025	8-K	Current Report
May 14, 2025	10-Q	Quarterly Report
May 7, 2025	8-K	Current Report

View All SEC Filings